GHRS · GH Research
AI read · Neutral
The AI's read
The story adds no new results about GH Research or its drug studies. RBC's unchanged view is one firm's opinion, not a change in the company's business, so it does not change the outlook.
RBC kept its Buy rating and $42 price target unchanged. This is an analyst's continuing opinion, not new information about GH Research's business, so the outlook is unchanged.
The story adds no new results about GH Research or its drug studies. RBC's unchanged view is one firm's opinion, not a change in the company's business, so it does not change the outlook.
Follow GH Research (GHRS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GHRS